Skip to main content

Human psychopharmacology: Efficacy and effectiveness of CNS drugs in psychiatric disorders

Guest Editors:
Renato de Filippis: University Magna Graecia of Catanzaro, Italy
Mohammadreza Shalbafan: Iran University of Medical Sciences, Iran

BMC Psychiatry welcomed submissions for the collection on “Human psychopharmacology: Efficacy and effectiveness of CNS drugs in psychiatric disorders.”

Modern clinical psychopharmacology can be dated to the introduction of lithium carbonate to treat mania in 1949. A year later, the introduction of chlorpromazine proved to be effective in the treatment of mania and psychotic disorders. Research in psychopharmacology continues on a path of evidence-based, methodological improvement, which endures today leading to significant progress in clinical practice. Innovation is essential for the identification of novel pharmacological therapies to meet the treatment needs of patients with psychiatric disorders. For this reason, we invited submissions covering various topics on the efficacy and effectiveness of central nervous system (CNS) drugs in psychiatric disorders.

New Content ItemThis collection supports and amplifies research related to SDG 3: Good Health & Wellbeing.

Meet the Guest Editors

Back to top

Renato de Filippis: University Magna Graecia of Catanzaro, Italy

Dr. Renato de Filippis is an Italian Early Career Adult Psychiatrist (ECP) and Research Fellow at the University Magna Graecia of Catanzaro. He currently works as clinician and researcher in the Psychiatric Unit.

Dr. de Filippis does research in clinical psychiatry, and he works as a clinical psychiatrist mainly dealing with schizophrenia and related disorders, psychopharmacology, clozapine-related DRESS syndrome, clinical psychiatry, and allied topics. He is regional delegate of Italian Society of Psychiatry – ECPs section and Editorial Board member of BMC Psychiatry.

Mohammadreza Shalbafan: Iran University of Medical Sciences, Iran

Dr. Mohammadreza Shalbafan is an Assistant Professor at Iran University of Medical Sciences.

He is interested in biological treatments in psychiatry, COVID-19, reducing stigma of psychiatric disorders and obsessive-compulsive disorder, education in psychiatry, and neuroscience. He has published numerous articles in high level journals both in English and Persian and presented his works in many international congresses.

Dr. Shalbafan is a member of the Direction Board, Treasurer, and President of the Early Career Psychiatrists section of the Iranian Psychiatric Association.  He is a member of Early Career Psychiatrists section of World Psychiatric Association. He also serves as head of the Education Development Office (EDO) of School of Medicine and Head of Continuous Medical Education (CME) office at the Iran University of Medical Sciences. In addition, he is chair of Brain and Cognition Clinic. Additionally, he serves as an Editorial Board member of BMC Psychiatry. 

About the collection

BMC Psychiatry welcomed submissions for the collection on “Human psychopharmacology: Efficacy and effectiveness of CNS drugs in psychiatric disorders.”

Modern clinical psychopharmacology can be dated to the introduction of lithium carbonate to treat mania in 1949. A year later, the introduction of chlorpromazine proved to be effective in the treatment of mania and psychotic disorders. Research in psychopharmacology continues on a path of evidence-based, methodological improvement, which endures today leading to significant progress in clinical practice. Innovation is essential for the identification of novel pharmacological therapies to meet the treatment needs of patients with psychiatric disorders. For this reason, we invited submissions covering various topics on the efficacy and effectiveness of central nervous system (CNS) drugs in psychiatric disorders.

This collection supports and amplifies research related to SDG 3: Good Health & Wellbeing.

Image credit: fizkes / Getty images / iStock (Symbolbild mit Fotomodell)

  1. We report the final results of treatment with aripiprazole, blonanserin, and paliperidone from the Japan Useful Medication Program for Schizophrenia (JUMPs), a 104-week naturalistic study.

    Authors: Jun Ishigooka, Kazuyuki Nakagome, Tetsuro Ohmori, Nakao Iwata, Ken Inada, Jun-ichi Iga, Taro Kishi, Kiyoshi Fujita, Yuka Kikuchi, Toshiaki Shichijo, Hideaki Tabuse, Shotatsu Koretsune, Hiroshi Terada, Haruko Terada, Toshifumi Kishimoto, Yuichiro Tsutsumi…
    Citation: BMC Psychiatry 2024 24:600
    Content type: Research Published on:

  2. Major depressive disorder is one of the most common psychiatric disorders, which is associated with a high disease burden. Current treatments using antidepressants have limitations, so using medication with ne...

    Authors: Atefeh Zandifar, Maryam Panahi, Rahim Badrfam and Mostafa Qorbani
    Citation: BMC Psychiatry 2024 24:163
    Content type: Research Published on:

  3. Selective serotonin reuptake inhibitors (SSRIs) are widely used for the treatment of various mental disorders. Sexual dysfunction is one of the most common side effects of SSRIs, and often leads to poor adhere...

    Authors: Arman Alipour-Kivi, Negin Eissazade, Seyed Vahid Shariat, Razieh Salehian, Shiva Soraya, Sanaz Askari and Mohammadreza Shalbafan
    Citation: BMC Psychiatry 2024 24:67
    Content type: Research Published on:

  4. The utilization of once-monthly paliperidone palmitate (PP1M) in schizophrenia treatment has increased due to its enhanced adherence and convenience. However, there is limited evidence on patient characteristi...

    Authors: Qian Li, Xin Li, Chong Ye, Miaomiao Jia and Tianmei Si
    Citation: BMC Psychiatry 2024 24:57
    Content type: Research Published on:

  5. To explore the influence of CYP2D6 genetic polymorphism on risperidone metabolism, thereby affecting risperidone’s effects and safeties in patients with chronic schizophrenia.

    Authors: Xiaoyi Wang, Jing Huang, Jianjun Lu, Xuemei Li, Hui Tang and Ping Shao
    Citation: BMC Psychiatry 2024 24:41
    Content type: Research Published on:

  7. As 40–60% of the patients with obsessive-compulsive disorder (OCD) do not adequately respond to the first-line treatment, finding an effective second-line treatment is required. Our aim was to assess the effic...

    Authors: Marjan Shokrani, Sanaz Askari, Negin Eissazade, Seyed Vahid Shariat, Behnam Shariati, Masoomeh Yarahmadi and Mohammadreza Shalbafan
    Citation: BMC Psychiatry 2023 23:686
    Content type: Research Published on:

Submission Guidelines

Back to top

This Collection welcomes submission of original Research Articles. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Human psychopharmacology: Efficacy and effectiveness of CNS drugs in psychiatric disorders" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.